A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction

European Journal of Heart Failure

Volumn 16, Issue 11, 2014, Pages 1175-1182

  Adabag, Selcuk ^a,b   Rector, Thomas S ^a,b   Anand, Inder S ^a,b   McMurray, John J ^c   Zile, Michael ^d   Komajda, Michel ^e   McKelvie, Robert S ^f   Massie, Barry ^g   Carson, Peter E ^h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e SORBONNE UNIVERSITÉ   (France)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

Author keywords

Death, sudden; Heart failure; Prognosis; Risk factors

Indexed keywords

IRBESARTAN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; COMPLICATION; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HEART STROKE VOLUME; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL;

AGED; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE VOLUME; SURVIVAL ANALYSIS;

EID: 84916600098     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.172     Document Type: Article

References (38)

1. Myerburg RJ, Castellanos A,. Cardiac Arrest and Sudden Cardiac Death. In:, Bonow RO, Mann DL, Zipes DP, Libby P, editors. Braunwald's Heart Disease-A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier Saunders; 2014. p845- 884.
2. Deo R, Albert CM,. Epidemiology and genetics of sudden cardiac death. Circulation 2012; 125: 620-637.
3. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE,. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010; 121: 1393-1405.
4. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA,. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581-2588.
5. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL,. Sudden death after myocardial infarction. JAMA 2008; 300: 2022-2029.
6. Chan MM, Lam CS,. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15: 604-613.
7. Myerburg RJ, Reddy V, Castellanos A,. Indications for implantable cardioverter-defibrillators based on evidence and judgment. J Am Coll Cardiol 2009; 54: 747-763.
8. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ,. Out-of- hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-1209.
9. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, McAnulty JH, Gunson K, Jui J, Chugh SS,. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161-1166.
10. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ,. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500-1505.
11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM,. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
12. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP,. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
13. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D,. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119: 3070-3077.
14. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M,. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214-1220.
15. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL,. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-2216.
16. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757.
17. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV,. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 2012; 18: 749-754.
18. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA,. Effect of candesartan on cause- specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-2183.
19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A,. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
20. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE,. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I- PRESERVE trial. Circ Heart Fail 2011; 4: 569-577.
21. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD,. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235.
22. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
23. Uno H, Tian L, Cai T, Kohane IS, Wei LJ,. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 2013; 32: 2430-2442.
24. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH,. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009; 120: 2170-2176.
25. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM,. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4: 27-35.
26. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, Josephson ME, Lehmann MH, Prystowsky EN,. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007; 50: 1150-1157.
27. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I,. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter- defibrillator. J Am Coll Cardiol 2012; 59: 2075-2079.
28. Adabag AS, Peterson G, Apple FS, Titus J, King R, Luepker RV,. Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation. Am Heart J 2010; 159: 33-39.
29. Davies MJ, Thomas A,. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140.
30. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T,. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975; 51: 606-613.
31. Kannel WB, Schatzkin A,. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985; 5 (6 Suppl): 141B-149B.
32. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S,. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013; 128: 2192-2201.
33. Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho O, Leppaluoto J, Huikuri HV,. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43: 757-763.
34. Scott PA, Barry J, Roberts PR, Morgan JM,. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail 2009; 11: 958-966.
35. Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG,. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 2005; 26: 2706-2713.
36. Steg PG, Lopez-Sendon J, Lopez de SE, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F,. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68-73.
37. Copas JB,. Using regression models for prediction: shrinkage and regression to the mean. Stat Methods Med Res 1997; 6: 167-183.
38. Van Houwelingen HC,. Validation, calibration, revision and combination of prognostic survival models. Stat Med 2000; 19: 3401-3415.